In 2024, the biopharmaceutical industry experienced a notable growth recovery, with 19 of the top 20 publicly traded global biopharma companies reporting revenue growth. The total revenue for these companies increased by over 7.9% to $880.4 billion from 2023 to 2024, as reported by GlobalData. Among the top performers were Eli Lilly, with a 32% revenue growth reaching $45 billion, and Novo Nordisk, showing a 25.5% increase to $42.1 billion, driven by the success of their obesity and diabetes blockbuster drugs.
Eli Lilly’s revenue surge was fueled by the strong sales of Mounjaro and Zepbound, generating $16.5 billion globally, along with the breast cancer drug Verzenio contributing $5.3 billion in sales. Novo Nordisk’s Ozempic and Wegovy amassed a combined $25.9 billion in global sales. Looking ahead, Eli Lilly is projected to continue its growth momentum with a forecasted 34.3% revenue increase to $59.2 billion in 2025, outpacing Novo Nordisk’s expected 16.4% growth to $47.7 billion in the same year.
Astellas Pharma also demonstrated robust performance in 2024, achieving a 19.2% revenue growth to $13.2 billion, primarily driven by the sales of Xtandi for prostate cancer, which recorded $5.98 billion in global sales. Pfizer and Roche experienced revenue recovery after declines in the previous year, with Pfizer’s revenue growing by 6.8% to $63.6 billion and Roche’s revenue increasing by 3% to $68.7 billion in 2024. Pfizer’s post-pandemic sales recovery is shifting towards non-Covid-19 products, particularly led by Eliquis generating $13.3 billion in global sales in 2024.
Several top biopharma companies recorded significant growth in operating profit in 2024, with Pfizer, Merck & Co, Eli Lilly, and Astellas Pharma reporting over 50% growth. On the other hand, Bristol Myers Squibb, Bayer, and Gilead Sciences saw more than a 50% decline in their operating profit. Merck & Co, Pfizer, Astellas, and Eli Lilly achieved remarkable growth in net profit, with Merck & Co leading at 4,589%, driven by operating income and absence of legal settlement charges. The industry also witnessed some companies reporting a decline in profitability, mainly attributed to impairment charges and research and development expenses.
Looking ahead, the top biopharmaceutical companies are expected to face challenges in maintaining the growth momentum in 2025. Factors such as loss of exclusivity for major drugs and drug pricing pressures in the US could impact revenue growth. However, companies like Eli Lilly are positioned to continue outperforming their peers, particularly in the obesity and diabetes segments. The recovery of companies like Pfizer and Roche from post-pandemic revenue losses through diversified product portfolios reflects a resilient approach to market dynamics and evolving consumer needs.
Takeaways:
– Biopharma industry witnessed a significant revenue growth recovery in 2024, with top companies showing strong performance.
– Eli Lilly and Novo Nordisk led the revenue growth, driven by successful obesity and diabetes drugs.
– Companies like Pfizer and Roche are rebounding from pandemic-related revenue declines through diversified product offerings.
– Challenges lie ahead in 2025, including loss of exclusivity for major drugs and pricing pressures in the US market.
Tags: biopharma
Read more on pharmaceutical-technology.com